Search

Displaying results 271 - 280 of 1279 in total
  1. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.[A192546]

  2. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    [A242427] Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13. … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.

  3. Drug

    Vitamin D

    go.drugbank.com/drugs/DB11094
    ApprovedInvestigationalNutraceuticalVet approved

    Vitamin D3 and D2 require hydroxylation in order to become biologically active in the human body.

    Mixtures: TL-Fluorivite, Halibut Oil
  4. Drug

    Ouabain

    go.drugbank.com/drugs/DB01092
    Approved

    A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis.

  5. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued.

  6. Target

    Immunoglobulin heavy variable 3-23

    go.drugbank.com/bio_entities/BE0004165
    TargetHumans

    V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig heavy chain V-III region TIL
  7. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanof...

  8. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on

    Synonyms: Humanised anti-IL-6 receptor monoclonal antibody
  9. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. … In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.

  10. Drug

    Potassium chloride

    go.drugbank.com/drugs/DB00761
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release

    Mixtures: Tis-U-Sol, Tis-U-sol